Lucyd, Inc (LUCY) is a publicly traded company in the Healthcare — Medical - Instruments & Supplies industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Lucyd, Inc develops and sells smart eyewear in North America. It offers smart eyewear products to enable wearer to listen to music, take and make calls, and use voice assistants and ChatGPT to perform smartphone tasks hands-free, as well as prescription eyeglasses, ready-to-wear sunglasses, safety glasses, and sport glasses under the Lucyd Lyte, Lucyd Armor, Nautica, Eddie Bauer, and Reebok brand names.
Price
| Price | $0.86 |
| Market Cap | $5M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.77 |
| EV / EBITDA | -0.38 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -88.90% |
| Return on Invested Capital | -122.15% |
| Return on Assets | -102.86% |
| Gross Margin | 22.79% |
| Operating Margin | -249.03% |
| Net Margin | -225.28% |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 12.06 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -3.75 |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| LUCY | Lucyd, Inc | $5M | 0.77 | -88.9% | |
| 0R29.L | Intuitive Surgical, Inc. | $135.9B | 74.05 | 11.86 | 17.8% |
| ISRG | Intuitive Surgical, Inc. | $135.1B | 44.13 | 7.62 | 17.8% |
| 0R19.L | Becton, Dickinson and Company | $52.5B | 33.21 | 2.19 | 6.6% |
| BDX | Becton, Dickinson and Company | $50.1B | 55.54 | 2.08 | 3.8% |
| RMD | ResMed Inc. | $33.1B | 22.81 | 5.23 | 23.9% |
| 0KW4.L | ResMed Inc. | $31.1B | |||
| MDLN | Medline Inc. | $27.6B | 38.36 | 2.44 | 10.8% |
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of LUCY: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks